Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) saw unusually-strong trading volume on Monday . Approximately 41,178 shares traded hands during trading, an increase of 25% from the previous session’s volume of 33,020 shares.The stock last traded at $7.1850 and had previously closed at $7.1414.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xilio Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Xilio Therapeutics Price Performance

The stock has a market capitalization of $561.83 million, a P/E ratio of -11.54 and a beta of -0.05. The stock’s 50-day simple moving average is $8.09 and its 200 day simple moving average is $9.63.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bain Capital Life Sciences Investors LLC lifted its position in Xilio Therapeutics by 61.4% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock worth $4,720,000 after acquiring an additional 2,805,869 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Xilio Therapeutics in the fourth quarter valued at approximately $3,787,000. Empery Asset Management LP bought a new position in shares of Xilio Therapeutics during the fourth quarter worth approximately $757,000. Ghisallo Capital Management LLC bought a new position in shares of Xilio Therapeutics during the fourth quarter worth approximately $713,000. Finally, Renaissance Technologies LLC lifted its holdings in Xilio Therapeutics by 68.3% during the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after purchasing an additional 139,716 shares during the last quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.